Business Wire

PKU: Pre-Clinical Kinetic Data Showing Prolonged Release of Amino Acids Thanks to the Innovative Physiomimic Technology by APR Presented at the 13th ICIEM Congress (September 5th-8th, Rio de Janeiro)

Jaa

APR Applied Pharma Research s.a. (“APR”), the Swiss independent developer of science driven and patent protected healthcare products, announces today the results of a pre-clinical kinetic study showing a physiological absorption of clinically relevant groups of amino acids (AAs) thanks to the application of the patented Physiomimic™ drug delivery Technology platform. APR’s innovative product is intended to be used for the management of patients with phenylketonuria (PKU).

The results of the investigation indicate that the Physiomimic™ Technology by APR is able to modify the release of clinically relevant AAs by lowering and retarding their absorption profiles if compared to the same mix of amino acids without the application of the technology. Also remarkable is that the kinetic profile of the AAs engineered with the Physiomimic™ Technology resembles that of casein - a reference food protein known to have a prolonged absorption profile.

The study suggests that APR’s advanced formulation of AAs has the potential of contributing to maintain Phenylalanine (“PHE”) levels within the recommended ranges, with less prominent fluctuations of PHE levels over time, thanks to a prolonged release of the AAs in the gut, which is thought to allow a more efficient utilization of the absorbed amino acids, PHE included.
Furthermore, the Physiomimic™ Technology has the ability of remarkably masking their taste and odor, with potential positive consequences on aftertaste for an exceptionally palatable product.

The outcome of the pre-clinical study will be presented in an oral presentation (Gut Microbiota and Human Metabolism” Thursday September 7 th 2017, 11.00-12.30) during the 13th International Congress of Inborn Errors of Metabolism in Rio de Janeiro on September 5 - 8, 2017 (ICIEM 2017). A poster will also illustrate the results of the application of the innovative Physiomimic™ Technology (Attended Poster Session Wednesday September 6 th 17:30 – 20:00) to amino acids for PKU.

“For the first time, the application of a pharmaceutical drug delivery technology platform to a Medical Food leads to a real change in PKU management.” Paolo Galfetti, CEO of Applied Pharma Research, states. “Since data show that there are still open issues in the management of PKU, we developed the Physiomimic™ Technology with the aim of meaningfully contributing to fulfill significant unmet needs of this disorder, providing patients, Healthcare Professionals (HCPs) and care givers with a product that would deliver amino acids in a physiological manner, whilst being very palatable and thus significantly improving patient compliance”.

“The development plan to characterize our innovative product for PKU is robust, - adds Giorgio Reiner, Corporate Director R&D of Applied Pharma Research – “with the next major step being a clinical kinetic study in human volunteers as a proof of concept of the prolonged release of Amino Acids and their consequent physiological absorption. Other pre-clinical studies as well as clinical evidences will reinforce the scientific profile of our proprietary technology and product to help us continue this journey.

On October 5th-8th, APR will also sponsor the 31 st E.S. PKU Conference (European Society for Phenylketonuria and Allied Disorders Treated as Phenylketonuria), in Hell, Norway continuing to contribute to the advancement of the management of this rare disorder.

About APR Applied Pharma Research s.a.
APR is a Swiss, independent developer of science driven, patent protected Healthcare products. The Company identifies, develops and licenses science driven, value added products designed to address patient or consumer needs in selected therapeutic areas on a global basis. In particular, APR is currently focused on 2 (two) areas: (i) internally developed and financed (alone or together with our co-development partners) proprietary, value added products to be licensed to healthcare companies for their commercialization, and (ii) support to third party projects by offering added value R&D services under contract and fee for service arrangements. APR has a balanced pipeline of revenue generating branded products marketed in all major markets combined with a compelling pipeline of products at different stage of development. APR has entered into licensing and partnership agreements with pharmaceutical companies, in over 70 countries with international sales on a worldwide basis.

About Phenylketonuria or PKU
Phenylketonuria or PKU is a rare, genetic, recessive metabolic disorder affecting about 50.000 people worldwide. PKU is characterized by the deficiency or the malfunctioning of a liver enzyme needed to process phenylalanine (“PHE”), an essential amino acid found in most protein-containing food. Excessive amounts of PHE in the bloodstream become toxic to the brain, impairing the normal development of the central nervous system. If not properly treated, PKU leads to severe, non-recoverable mental retardation and major cognitive disabilities. PKU can only be treated through a strict, life-long, low-protein (low-PHE) dietetic treatment combined with a daily assumption of low-protein modified foods and Medical Food which provides PHE-free amino acids and other important nutrients, needed due to the dietary restrictions of PKU patients.

For more information about Physiomimic™ Technology, please visit: www.apr.ch/apr-pharma-products/medical-prescription/genetic-metabolic-disease/
For press releases and other company information visit: www.apr.ch

Contact information

APR Applied Pharma Research s.a.
Paolo Galfetti; CEO
T: +41 91 6957020
paolo.galfetti@apr.ch
or
Havas PR Milan - Press Office
Sara Bernabovi, T: +39 02 85457032
sara.bernabovi@havaspr.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Edgewater Networks Announces Event Sponsorship of BroadSoft Connections 201721.10.2017 00:00Tiedote

Edgewater Networks, Inc., the industry leader in Network Edge Orchestration, announced today that it is an event sponsor of the BroadSoft Connections 2017 user conference, which takes place October 22-25 at the JW Marriott Phoenix Desert Ridge Resort & Spa in Phoenix, AZ. During the event, Edgewater Networks will feature demonstrations of the latest end-to-end network interoperability capabilities, including Zero Touch Provisioning, UC Analytics from the core to the endpoint, SD-WAN optimized for BroadSoft, and much more. Continuing a long-standing partnership with BroadSoft, Edgewater Networks has completed another level of BroadCloud certification, this time for local survivability which is critical for business continuity for SMB and Enterprise customers. BroadSoft’s PacketSmart is available on all EdgeMarc Intelligent Edges. All elements of the Network Edge Orchestration are

More than 70 Companies to Showcase Top Tech at CES Unveiled Paris20.10.2017 18:08Tiedote

The Consumer Technology Association (CTA) today announced that more than 70 exhibitors will showcase their latest innovations at the now sold-out fifth annual CES Unveiled Paris The event will focus on the Internet of Things (IoT), connectivity and smart cities, and draw more than 600 attendees. CES Unveiled Paris will run from 2-7:30 PM on Tuesday, October 24, 2017 at the Palais Brongniart. Regional technology companies, top-tier media outlets, buyers and key industry influencers will come together at CES Unveiled Paris to get a direct look at the latest industry developments. The day kicks off with a CES news conference and CTA market trends presentation. Conference programming is followed by a tabletop exhibition & networking reception. Curated exhibitors will be there to showcase top tech from robotics and audio to smart home and augmented and virtual reality. Notable

Westinghouse Receives Regulatory Approval for Analysis Methodologies20.10.2017 15:15Tiedote

Westinghouse Electric Company today announced that it has received approval from the U.S. Nuclear Regulatory Commission (NRC) for two new important analysis methodologies that will be used to upgrade Westinghouse- and Combustion Engineering-based nuclear steam supply system (NSSS) safety analyses. The approvals granted are for the new FULL SPECTRUMTM Loss of Coolant Accident (FSLOCATM) methodology and the Performance Analysis and Design Model software code update, PAD5. FSLOCA is capable of improved modeling of the transient response in a pressurized water reactor to the full spectrum of LOCA break sizes that could occur, and PAD5 is the next generation of the Westinghouse fuel rod design performance code. “These codes were developed to work in concert with each other to maximize analytical margin for nuclear utilities,” said Michele DeWitt, senior vice preside

Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Rates in Difficult-to-Cure HCV Patients and Improved Long-Term Bone and Renal Safety of Vemlidy® in HBV Patients Switched from Viread®20.10.2017 15:03Tiedote

Gilead Sciences, Inc. (NASDAQ: GILD) today announced results from Phase 2 and Phase 3 studies of its approved medicines for chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection, adding to the body of evidence supporting Gilead’s viral hepatitis therapies in diverse patient populations. These and other data from more than 25 abstracts will be presented this week at The Liver Meeting® 2017, which begins today in Washington, D.C. Positive results from studies of Harvoni® (ledipasvir 90mg/sofosbuvir 400mg) in HCV-infected patients with severe renal impairment, Epclusa® (sofosbuvir 400mg/velpatasvir 100mg) in HCV-infected liver transplant recipients and Vosevi® (sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg) in NS5A-inhibitor experienced HCV-infected patients will be presented during poster sessions on October 21 and October 22. In addition, updated results f

SP3H Announces That It Has Obtained a €1.2 Million European Union Grant for Its Intelligent and Clean Vehicle (VIP) Project20.10.2017 13:47Tiedote

SP3H is proud to announce joining the very select circle of the 10 French winners of the H2020 SME Instrument Phase 2 program since 2014. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171020005325/en/ Last summer VIP received the very prestigious SME instrument phase 2 H2020 label in the "transport & smart cities mobility" category. With an overall budget of € 1.7 million, VIP is subsidized by the European Union at a rate of 70% or €1.2 million. The framework contract was officially signed early October. VIP is the pre-industrialization program for Fuelbox sensors, the world's first miniaturized scanner capable of analyzing the quality of fuels on board vehicles. The heart of the program remains closely linked to the reduction of CO2 and pollutant emissions from vehicle

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme